Mifepristone at Same Time Multicenter Study
Mifepristone at Same Time Multicenter Study
This is a multicenter, randomized study. 564 healthy women, age 18 years or older, with an
 intrauterine pregnancy, and requesting a medical abortion, will be recruited to participate
 in this prospective clinical trial. This study will provide an evaluation of oral
 mifepristone 200 mg and vaginal misoprostol 800 mcg administered simultaneously in women up
 to 63 days gestation. The aims of the study are to compare the complete abortion rates, at 7
 and 14 days after misoprostol administration, when using mifepristone 200 mg orally and
 misoprostol 800 mcg vaginally are administered simultaneously and 24 hours apart in women up
 to 63 days gestation. Assessment of side effects (nausea, vomiting, pain) as well as
 acceptability will be done using pre and post-study questionnaires, and visual analogue
 scales. Complete abortion rate within 24 hours is expected to be 90%
This is a multicenter, randomized study. 564 healthy women, age 18 years or older, with an
 intrauterine pregnancy, and requesting a medical abortion, will be recruited to participate
 in this prospective clinical trial. This study will provide an evaluation of oral
 mifepristone 200 mg and vaginal misoprostol 800 mcg administered simultaneously in women up
 to 63 days gestation. The aims of the study are to compare the complete abortion rates, at 7
 and 14 days after misoprostol administration, when using mifepristone 200 mg orally and
 misoprostol 800 mcg vaginally are administered simultaneously and 24 hours apart in women up
 to 63 days gestation. Assessment of side effects (nausea, vomiting, pain) as well as
 acceptability will be done using pre and post-study questionnaires, and visual analogue
 scales. Complete abortion rate within 24 hours is expected to be 90%.
Inclusion Criteria:pregnancy equal to or less than 63 days at enrollment -

 Exclusion Criteria:abnormal pregnancy diagnosed by ultrasound

 -